Literature DB >> 30975503

Discovery, synthesis, biological evaluation and molecular docking study of (R)-5-methylmellein and its analogs as selective monoamine oxidase A inhibitors.

Chao Huang1, Juan Xiong1, Hui-Da Guan2, Chang-Hong Wang2, Xinsheng Lei3, Jin-Feng Hu4.   

Abstract

(R)-5-Methylmellein (5-MM), the major ingredient in the fermented mycelia of the medicinal fungus Xylaria nigripes (called Wuling Shen in Chinese)¸ was found to be a selective inhibitor against monoamine oxidase A (MAO-A) and might play an important role in the clinical usage of this edible fungus as an anti-depressive traditional Chinese medicine (TCM). Based on the discovery and hypothesis, a variety of (R)-5-MM analogs were synthesized and evaluated in vitro against two monoamine oxidase isoforms (MAO-A and MAO-B). Most synthetic analogs showed selective inhibition of MAO-A with IC50 values ranging from 0.06 to 29 µM, and compound 13aR is the most potent analog with high selectivity (IC50, MAO-A: 0.06 µM; MAO-B: >50 µM). Interestingly, the enzyme kinetics study of 13aR indicated that this ligand seemed to bind in the MAO-A active site according to so-called "tight-binding inhibition" mode. The molecular docking study of 13aR was thereafter performed in order to rationalize the obtained biological results.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  5-Methylmellein; Inhibitor; Monoamine oxidase; Natural product; Synthetic analogs

Mesh:

Substances:

Year:  2019        PMID: 30975503     DOI: 10.1016/j.bmc.2019.03.060

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  5 in total

1.  Copper-Catalyzed Enantioselective Hydroalkoxylation of Alkenols for the Synthesis of Cyclic Ethers.

Authors:  Dake Chen; Ilyas A Berhane; Sherry R Chemler
Journal:  Org Lett       Date:  2020-06-04       Impact factor: 6.005

Review 2.  Natural Products Inhibitors of Monoamine Oxidases-Potential New Drug Leads for Neuroprotection, Neurological Disorders, and Neuroblastoma.

Authors:  Narayan D Chaurasiya; Francisco Leon; Ilias Muhammad; Babu L Tekwani
Journal:  Molecules       Date:  2022-07-04       Impact factor: 4.927

3.  Design, Synthesis, and Biological Evaluation of Novel MAO-A Inhibitors Targeting Lung Cancer.

Authors:  Sanaa Bardaweel; Reem Aljanabi; Dima Sabbah; Kamal Sweidan
Journal:  Molecules       Date:  2022-04-30       Impact factor: 4.927

4.  Novel 1,3,4-thiadiazole compounds as potential MAO-A inhibitors - design, synthesis, biological evaluation and molecular modelling.

Authors:  Begüm Nurpelin Sağlık; Betül Kaya Çavuşoğlu; Ulviye Acar Çevik; Derya Osmaniye; Serkan Levent; Yusuf Özkay; Zafer Asım Kaplancıklı
Journal:  RSC Med Chem       Date:  2020-08-18

5.  Design, Synthesis, In Vitro and In Silico Studies of New Thiazolylhydrazine-Piperazine Derivatives as Selective MAO-A Inhibitors.

Authors:  Begüm Nurpelin Sağlık; Osman Cebeci; Ulviye Acar Çevik; Derya Osmaniye; Serkan Levent; Betül Kaya Çavuşoğlu; Sinem Ilgın; Yusuf Özkay; Zafer Asım Kaplancıklı
Journal:  Molecules       Date:  2020-09-22       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.